Compare OMEX & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OMEX | MCRB |
|---|---|---|
| Founded | 1986 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 52.9M | 47.4M |
| IPO Year | 2024 | 2015 |
| Metric | OMEX | MCRB |
|---|---|---|
| Price | $0.80 | $5.56 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $14.00 |
| AVG Volume (30 Days) | ★ 301.8K | 55.5K |
| Earning Date | 05-11-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | $9,327.00 | ★ $789,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.59 | $4.32 |
| 52 Week High | $4.43 | $29.98 |
| Indicator | OMEX | MCRB |
|---|---|---|
| Relative Strength Index (RSI) | 45.14 | 58.96 |
| Support Level | $0.74 | $5.31 |
| Resistance Level | $0.96 | $5.65 |
| Average True Range (ATR) | 0.06 | 0.33 |
| MACD | -0.01 | 0.16 |
| Stochastic Oscillator | 9.25 | 77.14 |
Odyssey Marine Exploration Inc is a deep-ocean exploration company. It discovers, validates, and develops high-value seafloor mineral resources and provides specialized mineral exploration, project development, and marine services to its clients. The company's subsea project portfolio contains multiple projects in various stages of development, such as the Phosagmex Project, a rich deposit of phosphate sands located seventy-ninety meters deep within the Mexican EEZ; two polymetallic nodule exploration license holders in the Cook Islands' EEZ; the Lihir Gold Project, a subsea area that contains several prospective gold exploration targets located in the Papua New Guinea Exclusive Economic Zone (EEZ); and others.
Seres Therapeutics Inc is a clinical-stage biotechnology company focused on the development of live biotherapeutic candidates. Its pipeline includes candidates such as SER-155 and SER-603, aimed at preventing and treating bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases. The company operates as a single reportable segment, mainly developing microbiome-based therapies targeting bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases.